A-620223

A-620223 is a PARP-1 inhibitor with a Ki of 8 nM against PARP-1 and EC50 of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) (HY-17364) and in an MX-1 breast xenograph model in combination with Cisplatin (HY-17394) . A-620223 can be used for the studies of melanoma and breast cancer[1].

Product Specifications

CAS Number

[272769-49-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PARP

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Field of Research

Cancer

Purity

98.84

Smiles

CCCN(CC1)CCC1C2=NC3=C(C(N)=O)C=CC=C3N2

Molecular Formula

C16H22N4O

Molecular Weight

286.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Penning TD, et al. Discovery and SAR of 2- (1-propylpiperidin-4-yl) -1H-benzimidazole-4-carboxamide: A potent inhibitor of poly (ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem. 2008 Jul 15;16 (14) :6965-75.